Gaucher Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Gaucher Disease stocks.

Gaucher Disease Stocks Recent News

Date Stock Title
May 17 SNY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
May 17 SNY Could Novavax Become the Next Moderna?
May 16 SNY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 SNY Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 SNY If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
May 15 PLX PLX: First Quarter Update
May 15 SNY Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
May 15 SNY Novavax Stock Just Tripled. Is It Too Late to Buy?
May 14 SNY Sanofi to make €1bn biomanufacturing investment in France
May 14 SNY Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
May 14 SNY Trending tickers: Anglo American, GameStop, Vodafone, Greggs and Novavax
May 14 SNY Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 14 SNY Exploring Three Dividend Stocks On Euronext Paris
May 13 SNY Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio with Strategic Additions in Q1 2024
May 13 SNY Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
May 13 SNY Meme Mania is Back: Buy these 3 Stocks
May 13 SNY Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
May 13 SNY Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
May 13 SNY Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
May 13 SNY Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
Gaucher Disease

Gaucher's disease or Gaucher disease () (GD) is a genetic disorder in which glucocerebroside (a sphingolipid, also known as glucosylceramide) accumulates in cells and certain organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet count and enlargement of the liver and spleen, and is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as glucosylceramidase), which acts on glucocerebroside. When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells and especially in macrophages (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain, and bone marrow.
Manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders or bone lesions that may be painful, severe neurological complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelet count, and yellow fatty deposits on the white of the eye (sclera). Persons seriously affected may also be more susceptible to infection. Some forms of Gaucher's disease may be treated with enzyme replacement therapy.
The disease is caused by a recessive mutation in the GBA gene located on chromosome 1 and affects both males and females. About one in 100 people in the United States are carriers of the most common type of Gaucher disease. The carrier rate among Ashkenazi Jews is 8.9% while the birth incidence is one in 450.Gaucher's disease is the most common of the lysosomal storage diseases. It is a form of sphingolipidosis (a subgroup of lysosomal storage diseases), as it involves dysfunctional metabolism of sphingolipids.The disease is named after the French physician Philippe Gaucher, who originally described it in 1882.

Browse All Tags